β-Defensin 43 inhibitors represent a specialized group of chemical entities designed to specifically modulate the activity of β-defensin 43, a member of the defensin family known for its role in the immune system. Defensins are small cationic peptides that are an integral part of the innate immune response in various organisms, acting primarily through their ability to disrupt microbial membranes and signal various immune responses. β-Defensin 43 is a unique defensin subtype, distinguished by its specific sequence motifs and structural properties that contribute to its distinct functional roles within the broader defensin family. Inhibitors targeting β-defensin 43 are engineered to interact directly with the peptide or its receptor interactions, thereby modifying its natural biological activity. These inhibitors are typically small molecules or peptides themselves that are structurally designed to bind to specific domains of β-defensin 43, interfering with its ability to engage with microbial membranes or immune receptors.
The design and synthesis of β-defensin 43 inhibitors require a deep understanding of the peptide's structural conformation and functional domains. Structural biology techniques such as X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy are often employed to elucidate the precise binding interactions between β-defensin 43 and its inhibitors. Computational methods, including molecular docking and dynamic simulations, are used to predict the most effective binding modes and to optimize the inhibitor structures for enhanced specificity and affinity. Additionally, biophysical assays, such as surface plasmon resonance and isothermal titration calorimetry, are essential for characterizing the binding kinetics and thermodynamics of these interactions. The inhibition of β-defensin 43 activity through these specialized inhibitors provides a valuable tool for probing the peptide's role in various biological processes, including its interactions with microbial pathogens and its involvement in modulating the immune response. This detailed understanding of β-defensin 43 inhibition can offer significant insights into the broader functions and regulatory mechanisms of defensins in host defense and immunity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
EGFR kinase inhibitor disrupting the MAPK/ERK pathway. Erlotinib indirectly inhibits β-defensin 43 by interfering with the EGFR/MAPK/ERK pathway, known to modulate β-defensin 43 transcription through specific transcription factors. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI3K/mTOR dual inhibitor affecting the PI3K/AKT/mTOR pathway. PI-103 indirectly suppresses β-defensin 43, as the PI3K/AKT/mTOR pathway regulates β-defensin 43 transcription through specific transcription factors. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting PI3K/AKT signaling. LY294002 indirectly suppresses β-defensin 43, as PI3K/AKT signaling regulates β-defensin 43 transcription through specific transcription factors. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor disrupting mTOR signaling. Rapamycin indirectly influences β-defensin 43 expression by interfering with the mTOR pathway, known to modulate β-defensin 43 transcription through specific transcription factors. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
p38 MAPK inhibitor affecting the MAPK pathway. SB203580 indirectly inhibits β-defensin 43 by disrupting the p38 MAPK pathway, known to modulate β-defensin 43 transcription through specific transcription factors. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor disrupting PI3K/AKT signaling. Wortmannin indirectly suppresses β-defensin 43, as PI3K/AKT signaling regulates β-defensin 43 transcription through specific transcription factors. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor impacting NF-κB signaling. Bortezomib indirectly hampers β-defensin 43 expression by blocking the proteasome, affecting the degradation of IκB and subsequent NF-κB activation, a pathway known to modulate β-defensin 43 transcription through specific transcription factors. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $148.00 $452.00 | 1 | |
H3K27 methyltransferase inhibitor. GSK343 indirectly influences β-defensin 43 by altering histone methylation, impacting the chromatin structure and accessibility of the β-defensin 43 gene for transcription. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor modulating chromatin structure. Trichostatin A indirectly suppresses β-defensin 43 by altering histone acetylation, influencing the accessibility of the β-defensin 43 gene for transcription. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
DNA-damaging agent affecting multiple pathways. Cisplatin indirectly influences β-defensin 43 by causing DNA damage, triggering various stress response pathways that modulate β-defensin 43 transcription through specific transcription factors. | ||||||